Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6541 to 6555 of 7680 results

  1. Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]

    Discontinued [GID-TAG420]

    Technology appraisal guidance
    Discontinued

  2. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued [GID-TAG526]

    Technology appraisal guidance
    Discontinued

  3. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued [GID-TA10157]

    Technology appraisal guidance
    Discontinued

  4. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued [GID-TA10363]

    Technology appraisal guidance
    Discontinued

  5. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued [GID-TA10072]

    Technology appraisal guidance
    Discontinued

  6. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued [GID-TAG424]

    Technology appraisal guidance
    Discontinued

  7. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued [GID-TAG337]

    Technology appraisal guidance
    Discontinued

  8. Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

    Discontinued [GID-TA10070]

    Technology appraisal guidance
    Discontinued

  9. Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]

    Discontinued [GID-TA10923]

    Technology appraisal guidance
    Discontinued

  10. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued [GID-TAG421]

    Technology appraisal guidance
    Discontinued

  11. PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)

    This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.

    Medtech innovation briefing
    Published
    25 March 2019

  12. UroShield for preventing catheter-associated urinary tract infections (MIB191)

    This advice has been updated and replaced by NICE medical technologies guidance 69.

    Medtech innovation briefing
    Published
    9 September 2019

  13. Alpha-Stim AID for anxiety (MIB193)

    This advice has been updated and replaced by NICE medical technologies guidance 56.

    Medtech innovation briefing
    Published
    16 September 2019

  14. DyeVert for reducing contrast media in coronary and peripheral angiography (MIB196)

    This advice has been updated and replaced by NICE medical technologies guidance 60.

    Medtech innovation briefing
    Published
    4 November 2019

  15. LiverMultiScan for liver disease (MIB181)

    This medtech innovation briefing has been updated and replaced by NICE diagnostics guidance on MRI-based technologies for assessing non-alcoholic fatty liver disease (DG50).

    Medtech innovation briefing
    Published
    26 April 2019